Fig. 5

Trametinib combined with PD-1/PD-L1 blockade reduces tumor growth in murine KRAS-mutant lung cancer syngeneic models. A Upper panel: Schematic of the experiment. Subcutaneously inoculated KRAS-mutant 393P cells were allowed to growth in syngeneic mice for 9 days. Tumor-bearing mice were randomized in four groups and treated with anti-PD-1 (Anti-PD-1; twice weekly; n = 8 mice per group), trametinib (TRAM; 5 days per week; n = 8 mice per group), their combination (TRAM + anti-PD-1; n = 8 mice per group) or vehicle (control; n = 8 mice per group). Lower panel from left to right: Follow-up of tumor volume over time. Tumor volumes at day 34 of all the experimental groups. Tumor volumes at day 74 of 393P-tumors treated with trametinib alone (TRAM) or in combination with anti-PD-1 (TRAM + anti-PD-1). Kaplan–Meier survival curves for all the experimental groups. B Upper panel: Schematic of the experiment. Subcutaneously inoculated KRAS-mutant LLC cells were allowed to growth in syngeneic mice for 7 days. Tumor-bearing mice were randomized in four groups and treated with anti-PD-1 (Anti-PD-1; twice weekly; n = 6 mice per group), trametinib (TRAM; 5 days per week; n = 6 mice per group), their combination (TRAM + anti-PD-1; n = 6 mice per group) or vehicle (control; n = 6 mice per group). Lower panel from left to right: Follow-up of tumor volume over time. Tumor volumes at day 21 of all the experimental groups. Tumor volumes at day 26 of LLC-tumors treated with trametinib alone (TRAM) or in combination with anti-PD-1 (TRAM + anti-PD-1). Data are expressed as mean ± SD. Comparisons between two experimental groups were performed by two-side t-test; for more than two experimental groups one-way ANOVA followed by the Tukey post hoc test was used